Intragastric application of aspirin, clopidogrel, cilostazol, and BPC 157 in rats: platelet aggregation and blood clot
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Report any unusual symptoms to your provider.
It designates what substances and methods are prohibited both in- and out-of-competition and which substances are banned in particular sports
Great service as usual Product Specifications Research-grade, manufacturer-verified Lyophilised powder Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val ~1.4 kDa 15 (pentadecapeptide) -20C (lyophilised), 2-8C (reconstituted) Bacteriostatic water or sterile saline Research Use Only: These products are intended for laboratory research use only and are not approved for human consumption
Copper peptides are recognised for promoting wound healing, boosting collagen production, and reducing inflammation three essential factors for acne-prone skin treatment and preventing post-acne scarring